Jähnichen Sven, Eltze Manfrid, Pertz Heinz H
Institute of Pharmacy, Free University of Berlin, Königin-Luise-Str. 2+4, Berlin 14195, Germany.
Eur J Pharmacol. 2004 Mar 19;488(1-3):157-67. doi: 10.1016/j.ejphar.2004.02.020.
The present study characterizes the alpha(1)-adrenoceptor subtypes mediating contractions to noradrenaline in isolated ring preparations of rat tail artery. Concentration-response (E/[A]) curves to noradrenaline were apparently monophasic (pEC(50) 6.47) but became biphasic in the presence of the selective alpha(1A)-adrenoceptor antagonist (+/-)-1,3,5-trimethyl-6-[[3-[4-((2,3-dihydro-2-hydroxymethyl)-1,4-benzodioxin-5-yl)-1-piperazinyl]propyl]amino]-2,4(1H,3H)-pyrimidinedione (B8805-033). Whereas the first phase of contraction to noradrenaline remained nearly unaffected in the presence of B8805-033 (0.03-3 microM), the second phase was concentration-dependently shifted to the right (pK(B) 8.06). In the presence of B8805-033 (3 microM), noradrenaline-induced contractions (pEC(50) 6.55) were antagonized in a competitive manner by prazosin (pK(B) 9.24), tamsulosin (pK(B) 8.55), 2-(2,6-dimethoxyphenoxyethyl)aminomethyl-1,4-benzodioxane (WB 4101; pK(B) 7.81), spiperone (pK(B) 7.69), 4-amino-2-[4-[1-(benzyloxycarbonyl)-2(S)-[[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline (L-765,314; pK(B) 7.31), 5-methylurapidil (pK(B) 6.55), 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione (BMY 7378; pK(B) 6.43), and 8-[2-(1,4-benzodioxan-2-ylmethylamino)ethyl]-8-azaspiro[4.5]decane-7,9-dione (MDL 73005EF; pK(B) 5.71), and were also antagonized by 100 microM chloroethylclonidine. N-[2-(2-cyclopropylmethoxyphenoxy)ethyl]-5-chloro-alpha,alpha-dimethyl-1H-indole-3-ethanamine (RS-17053) behaved as a noncompetitive antagonist (apparent pA(2) 6.55). Antagonist affinities obtained under these experimental conditions correlated highly with affinities at native and cloned alpha(1B)-adrenoceptors. Pretreatment of arterial rings with B8805-033 (3 microM) followed by receptor inactivation with chloroethylclonidine (100 microM) yielded monophasic E/[A] curves to noradrenaline (pEC(50) 6.14). Noradrenaline-induced contractions were competitively antagonized by tamsulosin (pK(B) 10.32), 5-methylurapidil (pK(B) 8.66), RS-17053 (pK(B) 8.44), B8805-033 (pK(B) 7.87), BMY 7378 (pK(B) 6.54), and L-765,314 (pK(B) 6.41). Antagonist affinities obtained under these experimental conditions correlated highly with affinities at native and cloned alpha(1A)-adrenoceptors. It is concluded that the contraction to noradrenaline in rat tail artery is mediated by both alpha(1B)- and alpha(1A)-adrenoceptors, each component of contraction being separable by use of selective alpha(1A)-adrenoceptor blockade and alpha(1B)-adrenoceptor alkylation, respectively.
本研究对介导大鼠尾动脉离体环制剂中去甲肾上腺素收缩作用的α₁ - 肾上腺素能受体亚型进行了表征。去甲肾上腺素的浓度 - 反应(E/[A])曲线明显呈单相(pEC₅₀ 6.47),但在选择性α₁A - 肾上腺素能受体拮抗剂(±)-1,3,5 - 三甲基 - 6 - [[3 - [4 - ((2,3 - 二氢 - 2 - 羟甲基)-1,4 - 苯并二恶英 - 5 - 基)-1 - 哌嗪基]丙基]氨基]-2,4(1H,3H)-嘧啶二酮(B8805 - 033)存在时变为双相。在B8805 - 033(0.03 - 3 μM)存在下,去甲肾上腺素收缩的第一相几乎不受影响,而第二相则浓度依赖性地向右移动(pK₈ 8.06)。在B8805 - 033(3 μM)存在下,去甲肾上腺素诱导的收缩(pEC₅₀ 6.55)被哌唑嗪(pK₈ 9.24)、坦索罗辛(pK₈ 8.55)、2 - (2,6 - 二甲氧基苯氧基乙基)氨基甲基 - 1,4 - 苯并二恶烷(WB 4101;pK₈ 7.81)、螺哌隆(pK₈ 7.69)、4 - 氨基 - 2 - [4 - [1 - (苄氧羰基)-2(S)-[[(1,1 - 二甲基乙基)氨基]羰基]-哌嗪基]-6,7 - 二甲氧基喹唑啉(L - 765,314;pK₈ 7.31)、5 - 甲基乌拉地尔(pK₈ 6.55)、8 - [2 - [4 - (2 - 甲氧基苯基)-1 - 哌嗪基]乙基]-8 - 氮杂螺[4.5]癸烷 - 7,9 - 二酮(BMY 7378;pK₈ 6.43)和8 - [2 - (1,4 - 苯并二恶烷 - 2 - 基甲基氨基)乙基]-8 - 氮杂螺[4.5]癸烷 - 7,9 - 二酮(MDL 73005EF;pK₈ 5.71)以竞争性方式拮抗,并且也被100 μM氯乙可乐定拮抗。N - [2 - (2 - 环丙基甲氧基苯氧基)乙基]-5 - 氯 - α,α - 二甲基 - 1H - 吲哚 - 3 - 乙胺(RS - 17053)表现为非竞争性拮抗剂(表观pA₂ 6.55)。在这些实验条件下获得的拮抗剂亲和力与天然和克隆的α₁B - 肾上腺素能受体的亲和力高度相关。用B8805 - 033(3 μM)预处理动脉环,然后用氯乙可乐定(